“ Post-Hoc Analyses Support Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Uncontrolled Eosinophilic Asthma and Prior Exacerbations”, J of Skin, vol. 9, no. 1, p. s524, Jan. 2025, doi: 10.25251/skin.9.supp.524.